arrow
G

Gian Matteo Rigolin

University of Ferrara
H指数:41
被引数:6,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

更正:携带t(14;19)易位的慢性淋巴细胞白血病患者临床和转录组学特征:一项ERIC研究

Leukemia
IF13.4
2026-10-160
OAAI
Exploring the synergy between telomere length and genomic complexity in CLL

探索端粒长度与基因组复杂性在CLL中的协同作用

2026-01-230
OAAI
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

携带t(14;19)易位的慢性淋巴细胞白血病患者临床及转录组学特征:一项ERIC研究

Leukemia
IF13.4
2025-09-190
OAAI
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

慢性淋巴细胞白血病患者接受伊布替尼治疗的弥漫性大b细胞淋巴瘤的Richter转化: 危险因素和结果

Leukemia
IF13.4
2025-06-250
OAAI
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy
2024-10-102
OAAI
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis
2024-07-010
PRE
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023-06-292
OA
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518-VERITAS study
2023-01-125
OAAI
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Dec, 10.1038/s41375-022-01802-y, 2022)
LEUKEMIA
IF13.4
2023-01-121
OAAI
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
LEUKEMIA
IF13.4
2022-12-2429
OAAI
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
2022-11-2110
OAAI
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

在FCR治疗的慢性淋巴细胞白血病的真实多中心队列中,IGHV突变患者的长期益处

2022-10-103
PRE
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病和严重新型冠状病毒肺炎患者的血栓和出血并发症: 欧洲CLL研究计划ERIC的研究

2022-08-268
OAAI